

**СВЕДЕНИЯ об официальном оппоненте
(Согласие на оппонирование)**

Я, Макаров Вадим Альбертович,
(Фамилия, имя, отчество)

согласен быть официальным оппонентом

Борисевич Софии Станиславовны
(Фамилия, имя, отчество)

по кандидатской / докторской (подчеркнуть) диссертации на тему:

**«Алгоритм описания механизма противовирусной активности ингибиторов
мембранных вирусных белков методами молекулярного моделирования»**

по специальности 1.4.16. Медицинская химия

О себе сообщаю:

ученая степень доктор фармацевтических наук

шифр и наименование специальности – 15.00.02 Фармацевтическая химия,
фармакогнозия

ученое звание - нет

должность - Заведующий Лабораторией Биомедицинской химии, Главный Научный
Сотрудник

место и адрес работы (постоянной) Федеральное государственное учреждение
«Федеральный исследовательский центр «Фундаментальные основы биотехнологии»
Российской академии наук» адрес: 119071 Российская Федерация, г. Москва, Ленинский
проспект, дом 33, строение 2

место и адрес работы (по совместительству) - нет

Я согласен на включение и дальнейшую обработку моих персональных данных, необходимых для процедуры защиты диссертации соискателя, исходя из нормативных документов Правительства РФ, Минобрнауки России и ВАК, в том числе на размещение их в сети Интернет на сайте НИОХ СО РАН, на сайте ВАК, в единой информационной системе.

Перечень опубликованных работ по специальности оппонируемой диссертации
(за последние 5 лет):

1. Salina E.G., Ekins S., Makarov V.A. A Rapid Method for Estimation of the Efficacy of Potential Antimicrobials in Humans and Animals by Agar Diffusion Assay, Chem. Biol. & Drug Des., 2019, 93, 6, 1021-25 doi: 10.1111/cbdd.13427
2. Zorn K.M., Lane T.R., Russo D.P., Clark A.M., Makarov V., Ekins S. Multiple Machine Learning Comparisons of HIV Cell-based and Reverse Transcriptase Data Sets, Mol Pharm., 2019, 16, 1620-1632. doi: 10.1021/acs.molpharmaceut.8b01297.
3. Puhl A.C., Garzino Demo A., Makarov V.A., Ekins S. New targets for HIV drug discovery, Drug Discovery Today, 2019, 24, 1139-1147. doi.org/10.1016/j.drudis.2019.03.013
4. Spaggiari D., Cruchon S., Guinchard S., Vocat A., Blattes E., Pitteloud J., Ciullini L., Bardin C., Ivanyuk A., Makarov V., Ryabova O., Buclin T., Cole S., Decosterd A. L. Development and validation of a multiplex UHPLC-MS/MS method for the determination of the investigational antibiotic against multi-resistant tuberculosis macozinone (PBTZ169) and five active metabolites in human plasma, Plos One, 2019, 14(5):e0217139. doi: 10.1371/journal.pone.0217139.

5. Egorova A., Ekins S., Schmidtke M., Makarov V. Back to the Future: Advances in Development of Broad-Spectrum Capsid-Binding Inhibitors of Enteroviruses, *European Journal of Medicinal Chemistry*, 2019, 178, 606-622. doi: 10.1016/j.ejmech.2019.06.008
6. Wald J., Pasin M., Richter M., Walther C., Mathai N., Kirchmair J., Makarov V.A., Goessweiner-Mohr N., Marlovits T.C., Zanella I., Real-Hohn A., Verdaguer N., Blaas D., Schmidtke M. Cryo-EM structure of pleconaril-resistant rhinovirus-B5 complexed to the antiviral OBR-5-340 reveals unexpected binding site, *PNAS*, 2019, pii: 201904732. doi: 10.1073/pnas.1904732116.
7. Nunvar J., Hogan A., Buroni S., Savina S., Makarov V., Cardona S., Drevinek P. The effect of 2-thiocyanatopyridine derivative 11026103 on *Burkholderia cenocepacia*: resistance mechanisms and systemic impact, *Antibiotics*, 2019, 8(4). pii: E159. doi: 10.3390/antibiotics8040159.
8. Degiacomi G., Sammartino J.C., Chiarelli L.R., Riabova O., Makarov V., Pasca M.R. *Mycobacterium abscessus*, an emerging and worrisome pathogen among cystic fibrosis patients, *International Journal of Molecular Sciences*, 2019, 20(23). pii: E5868. doi: 10.3390/ijms20235868
9. Costabile G., Provenzano R., Azzalin A., Scoffone V., Chiarelli L., Rondelli V., Grillo I., Zinn T., Lepioshkin A., Savina S., Miro A., Quaglia F., Makarov V., Coenye T., Brocca P., Riccardi G., Buroni S., Ungaro F., PEGylated mucus-penetrating nanocrystals for lung delivery of a new FtsZ inhibitor against *Burkholderia cenocepacia* infection, *Nanomedicine*, 2020, 23:102113. doi: 10.1016/j.nano.2019.102113.
10. Lupien A., Shi-Yan Foo C., Savina S., Vocat A., Piton J., Monakhova N., Benjak A., Lamprecht D.A., Steyn A.J.C., Pethe K., Makarov V.A., Cole S.T. New 2-Ethylthio-4-methylaminoquinazoline Derivatives Inhibiting Two Subunits of Cytochrome bc1 in *Mycobacterium Tuberculosis*, *PlosPathogen*, 2020, 16 (1), e1008270 DOI: 10.1371/journal.ppat.1008270
11. Egorova A., Kazakova E., Jahn B., Ekins S., Makarov V., Schmidtke M. Novel pleconaril derivatives: influence of substituents in the isoxazole and phenyl rings on the antiviral activity against enteroviruses, *European Journal of Medicinal Chemistry*, 2020, 188, 12007. doi.org/10.1016/j.ejmech.2019.112007
12. Chiarelli L., Salina E., Mori G., Azhikina T., Riabova O., Lepioshkin A., Grigorov A., Forbak M., Madacki J., Orena B., Manfredi M., Gosetti F., Buzzi A., Degiacomi G., Sammartino J. C., Marengo E., Korduláková J., Riccardi G., Mikušová K., Makarov V., Pasca M. R. New insights into the mechanism of action of the thienopyrimidine antitubercular prodrug TP053, *ACS Infectious Diseases*, 2020, 6, 313. doi: 10.1021/acsinfecdis.9b00388.
13. Buroni S., Makarov V., Scoffone V.C., Trespidi G., Riccardi G., Chiarelli L.R., The cell division protein FtsZ as a cellular target to hit cystic fibrosis pathogens, *European Journal of Medicinal Chemistry*, 2020, 190, 112132. doi.org/10.1016/j.ejmech.2020.112132
14. Mori G., Orena B.S., Chiarelli L.R., Degiacomi G., Riabova O., Sammartino J.C., Makarov V., Riccardi G., Pasca M.R. Rv0579 is involved in the resistance to the TP053 antitubercular prodrug, *Frontiers in Microbiology*, 2020, 11, 292. doi.org/10.3389/fmicb.2020.00292
15. Chiarelli L.R., Scoffone V.C., Trespidi G., Barbieri G., Riabova O., Monakhova N., Porta A., Manina G., Riccardi G., Makarov V., Buroni S. Chemical, metabolic and cellular characterization of a FtsZ inhibitor effective against *Burkholderia cenocepacia*, *Front. Microbiol.*, 2020, 11, 562. doi.org/10.3389/fmicb.2020.00562
16. Volobueva A., Egorova A., Galochkina A., Ekins S., Zarubaev V., Makarov V. The Evolution of Pleconaril: Modified O-Alkyl Linker Analogs have Biological Activity

Towards Coxsackievirus B3 Nancy, *Molecules*, 2020, 25, E1345. doi:10.3390/molecules25061345

17. Novoselova E.A., Alimbarova L.M., Monakhova N.S., Lepioshkin A.Y., Ekins S., Makarov V.A., *In vivo* Activity of Pyrimidine-Dispirotripiperazinium in the Male Guinea Pig Model of Genital Herpes, *J Virol Antivir Res* 2020, 9, 1, 1000193. DOI: 10.37532/jva.2020.9(1).193
18. Makarov V., Mikusova K. Development of Macozinone for TB treatment: An Update, *Appl. Sci.* 2020, 10, 2269; doi:10.3390/app10072269
19. Makarov V., Salina E., Reynolds R.C., Kyaw Zin P.P., Ekins S. Molecule Property Analyses of Active Compounds for Mycobacterium Tuberculosis, *J. Med. Chem.* 2020. 63(17):8917-8955. 10.1021/acs.jmedchem.9b02075
20. Székely R., Rengifo-Gonzalez M., Singh V., Riabova O., Benjak A., Piton J., Cimino M., Kornobis E., Mizrahi V., Johnsson K., Manina G., Makarov V., Cole S.T. 6,11-Dioxobenzo[f]pyrido[1,2-a]indoleskill Mycobacterium tuberculosis by targeting iron-sulfur protein Rv0338c a putative redox sensor, *ACS Infection Diseases*, 2020, 6(11):3015-3025. 10.1021/acsinfecdis.0c00531.
21. Makarov V., Riabova O., Ekins S., Pluzhnikov N., Chepur S. The Past, Present and Future of RNA Respiratory Viruses: Influenza and Coronaviruses, *Pathogens and Disease*, 2020, V. 78, ftaa046. 10.1093/femspd/ftaa046.
22. Egorova A., Bogner E., Novoselova E., Zorn K. M., Ekins S., Makarov V. Dispirotripiperazine-core compounds, their biological activity with a focus on broad antiviral property, and perspectives in drug design, *European Journal of Medicinal Chemistry*, 2021, 211, 113014. 10.1016/j.ejmech.2020.113014
23. Chiarelli L.R., Degiacomi G., Egorova A., Makarov V., Pasca M.R. Nitric oxide-releasing compounds for lung infections treatment, *Drug Discovery Today*, 2021, 26, 2, 542-550. 10.1016/j.drudis.2020.10.027
24. Monakhova N., Korduláková J., Vocat A., Egorova A., Lepioshkin A., Salina E. G., Nosek J., Repková E., Zemanová J., Jurdáková H., Górová R., Roh J., Degiacomi G., Sammartino J. C., Pasca M. R., Cole S. T., Mikušová K., Makarov V. Design and synthesis of pyrano[3,2-b]indolones showing antimycobacterial activity, *ACS Infectious Diseases*, 2021, 7(1), 88-100. 10.1021/acsinfecdis.0c00622
25. Adfeldt R., Schmitz J., Kropff B., Thomas M., Monakhova N., Hölper J., Klupp B., Mettenleiter T., Makarov V., Bogner E., Diazadispiroalkane derivatives – new viral entry inhibitors, *Antimicrobial Agents and Chemotherapy*, 2021, 65, e02103-20. 10.1128/AAC.02103-20
26. Bogner E., Egorova A., Makarov V., Small molecules – perspective novel HCMV inhibitors, *Viruses*, 2021, 13, 474. 10.3390/v13030474
27. Egorova A., Jackson M., Gavrilyuk V., Makarov V. Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities, *Medicinal Research Reviews*, 2021, 41. 2350. 10.1002/med.21798
28. Donlin M., Lane T., Riabova O., Lepioshkin A., Xu E., Lin J., Makarov V., Ekins S. Discovery of 5-nitro-6-thiocyanatopyrimidines as inhibitors of *Cryptococcus neoformans* and *Cryptococcus gattii*, *ACS Medicinal Chemistry Letters*, 2021, 12(5), 774-78. 10.1021/acsmedchemlett.1c00038.
29. Gawriljuk V., Foil D., Puhl A., Zorn K., Lane T., Riabova O., Makarov V., Godoy A., Oliva G., Ekins S. Development of Machine Learning Models and the Discovery of a New Antiviral Compound Against Yellow Fever Virus, *Journal of Chemical Information and Modeling*, 2021, 61(8), 3804-3813. 10.1021/acs.jcim.1c00460.
30. Trespidi G., Scoffone V. C., Barbieri G., Marchesini F., Abualsha'ar A., Coenye T., Ungaro F., Makarov V., Migliavacca R., De Rossi E., Buroni S., Anti-staphylococcal activity of the FtsZ inhibitor C109, *Pathogens*, 2021, 10, 886. 10.3390/pathogens10070886

31. Egorova A., Salina E.G.; Makarov V. Targeting Non-Replicating Mycobacterium tuberculosis and Latent Infection: Alternatives and Perspectives (Mini-Review). *Int. J. Mol. Sci.* 2021, 22, 13317. 10.3390/ijms222413317
32. Lane T.R., Urbina F., Rank L., Gerlach J., Riabova O., Lepioshkin A., Kazakova E., Vocat A., Tkachenko V., Cole S., Makarov V., Ekins S. Machine Learning Models for Mycobacterium tuberculosis In Vitro Activity: Prediction and Target Visualization. *Mol Pharm.* 2022, 19, 674-689. 10.1021/acs.molpharmaceut.1c00791
33. Schmalstig A.A., Zorn K.M., Murci S., Robinson A., Savina S., Komarova E., Makarov V., Braunstein M., Ekins S. Mycobacterium abscessus Drug Discovery using Machine Learning, *Tuberculosis*, 2022, 132, 102168. 10.1016/j.tube.2022.102168
34. Gur'eva Y.A., Zalevskaya O.A., Shevchenko O.G., Slepukhin P.A., Makarov V.A., Kuchin A.V. Copper(II) complexes with terpene derivatives of ethylenediamine: synthesis, antibacterial, antifungal and antioxidant activity, *RSC Advances*, 2022, 12, 8841 – 8851. 10.1039/d2ra00223j
35. Alimbarova L, Egorova A, Riabova O, Monakhova N, Makarov V. A proof-of-concept study for the efficacy of dispirotripiperazine PDSTP in a rabbit model of herpes simplex epithelial keratitis. *Antiviral Res.* 2022, 202, 105327. 10.1016/j.antiviral.2022.105327.
36. Puhl A., Gomes G., Damasceno S., Godoy A., Noske G., Nakamura A., Gawriljuk V., Fernandes R., Monakhova N., Riabova O., Lane T., Makarov V., Veras, F., Batah S., Fabro A., Oliva G., Cunha F., Alves-Filho J., Cunha T., Ekins S. Pyronaridine Protects Against SARS-CoV-2 in Mouse, *ACS Infectious Diseases*, 2022, 8, 1147-1160. 10.1021/acsinfecdis.2c00091
37. Glenn S.M., Turapov O., Makarov V., Kell D.B., Mukamolova G. Dimethyl fumarate eliminates differentially culturable Mycobacterium tuberculosis in an intranasal murine model of tuberculosis, *Frontiers in Cellular and Infection Microbiology*, 2022, 12, 957287. 10.3389/fcimb.2022.957287
38. Riabova O., Egorova A., Lepioshkin A., Li Y., Voigt K., Kloss F., Makarov V. Thieno[2,3-d]pyrimidine-Core Compounds Show Activity Against Clinically Relevant Gram-Positive Bacteria, *ChemMedChem*, 2022, e202200207. 10.1002/cmdc.202200207.
39. Dohme A., Knoblauch M., Egorova A., Makarov V., Bogner E. Broad-spectrum antiviral diazadispiroalkane core molecules block attachment and cell-to-cell spread of herpesviruses, *Antiviral Research*, 2022, 105402. 10.1016/j.antiviral.2022.105402
40. Makarov V.A., Popov V.O. PDSTP Is the First Drug in Class to Treat Coronavirus Infection, *Herald of the Russian Academy of Sciences*, 2022, Vol. 92, No. 4, pp. 488–490. DOI: 10.1134/S1019331622040190
41. Nilov D., Schmidtke M., Makarov V., Svedas V. Search for Ligands Complementary to the 430-Cavity of Influenza Virus Neuraminidase by Virtual Screening, *Supercomputing Frontiers and Innovations*, 2022, 9, 2, 79-83. 10.14529/js_220207
42. Rank L., Puhl A.C., Havener T.M., Anderson E., Foil D.H., Zorn K.M., Monakhova N., Riabova O., Hickey A.J., Makarov V., Ekins S. Multiple Approaches to Repurposing drugs for Neuroblastoma, *Bioorganic & Medicinal Chemistry*, 2022, 73, 117043. 10.1016/j.bmc.2022.117043
43. Degiacomi G., Makarov V., Pasca M. R., Chiarelli L. R. New Drugs and Novel Cellular Targets against Tuberculosis, *Int. J. Mol. Sci.*, 2022, 23, 13680. 10.3390/ijms232213680
44. Scoffone V. C., Irudal S., Alshaar A.A., Piazza A., Trespidi G., Barbieri G., Makarov V., Migliavacca R., De Rossi E., Buroni S. Bactericidal and anti-biofilm activity of the FtsZ inhibitor C109 against *Acinetobacter baumannii*, *Antibiotics*, 2022, 11, 1571. 10.3390/antibiotics11111571
45. Salina E.G., Makarov V. Mycobacterium tuberculosis dormancy: how to fight a hidden danger, *Microorganisms*, 2022, 10, 2334. 10.3390/microorganisms10122334

46. Salina E., Postiglione U., Chiarelli L., Recchia D., Záhorská M., Lepioshkin A., Monakhova N., Pál A., Porta A., Zanonì G., Korduláková J., Kazakova E., Sassera D., Pasca M.R., Makarov V., Degiacomi G. A new benzothiazolthiazolidine derivative 11726172 is active in vitro, in vivo, and against non-replicating cells of *Mycobacterium tuberculosis*, *mSphere*, 2022, 21, 7(6), e0036922 10.1128/msphere.00369-22
47. Desfontaine V., Guinchard S., Marques S., Vocat A., Mouffi F., Versace F., Huser-Pitteloud J., Ivanyuk A., Bardinet C., Makarov V., Ryabova O., André P., Prod'Hom S., Chtioui H., Buclin T., Cole S. T., Decosterd L.A. Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine, *Journal of Chromatography B*, 2023, 123555, 10.1016/j.jchromb.2022.123555
48. Koryakova A., Shcherbakova V., Riabova O., Kazaishvili Y., Bolgarin R., Makarov V., Antituberculosis Macozinone Extended-Release Tablets To Enhance Bioavailability: a Pilot Pharmacokinetic Study in Beagle Dogs, *Microbiology Spectrum*, 2023, 11, e0232722. 10.1128/spectrum.02327-22
49. Lane T., Makarov V., Nelson J., Meeker R.B., Sanna G., Riabova O., Kazakova E., Monakhova N., Tsedilin A., Urbina F., Suchy A., Ekins S. N-phenyl-1-(phenylsulfonyl)-1H-1,2,4-triazol-3-amine as a new class of HIV-1 non-nucleoside reverse transcriptase inhibitor, *Journal of Medicinal Chemistry*, 2023, 66(9):6193-6217. 10.1021/acs.jmedchem.2c02055
50. Degiacomi G., Gianibbi B., Recchia D., Stelitano G., Truglio G.I., Marra P., Stamilla A., Makarov V., Chiarelli L.R., Manetti F., Pasca M.R. CanB, a druggable cellular target in *Mycobacterium tuberculosis*, *ACS Omega*, 2023, 8(28):25209-25220. 10.1021/acsomega.3c02311
51. Lane T., Fu J., Sherry B., Tarbet B., Hurst B. L., Riabova O., Kazakova E., Egorova A., Clarke P., Leser J. S., Frost J., Rudy M., Tyler K., Klose T., Volobueva A., Belyaevskaya S., Zarubaev V., Kuhn R., Makarov V., Ekins S. Efficacy of an isoxazole-3-carboxamide analog of pleconaril in mouse models of Enterovirus-D68 and Coxsackie B5, *Antiviral Research*, 2023, 216, 105654. 10.1016/j.antiviral.2023.105654
52. Egorova A., Richter M., Khrenova M., Dietrich E., Tsedilin A., Kazakova E., Lepioshkin A., Jahn B., Chernyshev V., Schmidtke M., Makarov V. Pyrrolo[2,3-e]indazole as a novel chemotype for both influenza A virus and pneumococcal neuraminidase inhibitors, *RSC Adv.*, 2023, 13, 18253. 10.1039/d3ra02895j
53. Fan D., Wang B., Stelitano G., Savková K., Riabova O., Shi R., Wu X., Chiarelli L., Mikušová K., Makarov V., Lu Y., Hong Y., Qiao C. Side Chain-modified Benzothiazinone Derivatives with Anti-*Mycobacterial* Activity, *Biomedicines*, 2023, 11, 1975. 10.3390/biomedicines11071975
54. Jones, T., Tavis, J. E., Li, Q., Riabova, O., Monakhova, N., Bradley, D. P., Lane, T. R., Makarov, V., Ekins, S. Antiviral Evaluation of Dispirotripiperazines against Hepatitis B Virus. *Journal of Medicinal Chemistry*, 2023, 66(17):12459-12467. 10.1021/acs.jmedchem.3c00974.
55. Kazakova E., Lane T., Jones T., Puhl A., Riabova O., Makarov V., Ekins S. 1-Sulfonyl-3-amino-1H-1,2,4-triazoles as yellow fever virus inhibitors: synthesis and structure-activity relationship, *ACS Omega*, 2023, 8, 45, 42951–42965. 10.1021/acsomega.3c06106
56. Jones T., Monakhova N., Guivel-Benhassine F., Lepioshkin A., Bruel T., Lane T.R., Schwartz O., Puhl A. C., Makarov V., Ekins S. Synthesis and evaluation of 9-aminoacridines with SARS-CoV-2 antiviral activity, *ACS Omega*, 2023, 8(43), 40817-40822. 10.1021/acsomega.3c05900
57. Wu X., Wang W., Stelitano G., Riabova O., Wang B., Niu W., Cocorullo M., Shi R., Chiarelli L.R., Makarov V., Lu Y., Li C., Qiao C. Benzothiozinone derivatives with anti-

- tubercular Activity-Further side chain investigation. Eur J Med Chem. 2024, 264, 115976. doi: 10.1016/j.ejmech.2023.115976.
58. Tsedilin A., Borets L., Riabova O., Kazakova E., Tafeenko V., Makarov V. Determination of Alkaloid-Inspired Molecule Vindeburnol in Rabbit Plasma by UPLC–HRMS and its Application to Pharmacokinetic Studies and Preliminary Metabolite Identification, Journal of Pharmaceutical and Biomedical Analysis, 2024, 239, 115917. 10.1016/j.jpba.2023.115917.
59. Zubkov E., Riabova O., Zorkina Y., Egorova A., Ushakova V., Lepioshkin A., Novoselova E., Abramova O., Morozova A., Chekhonin V., Makarov V. Antidepressant-like Effect of the Eburnamine-Type Molecule Vindeburnol in Rat and Mouse Models of Ultrasound-Induced Depression, ACS Chemical Neuroscience, 2024, 10.1021/acscchemneuro.3c00590.
60. Richter M., Döring K., Blaas D., Riabova O., Khrenova M., Kazakova E., Egorova A., Makarov V., Schmidtke M. Molecular mechanism of rhinovirus escape from the Pyrazolo[3,4-d]pyrimidine capsid-binding inhibitor OBR-5-340 via mutations distant from the binding pocket: Derivatives that brake resistance, Antiviral Research, 2024, 105810. 10.1016/j.antiviral.2024.105810
61. Bonacorsi A., Trespidi G., Scoffone V. C., Irudal S., Barbieri G., Riabova O., Monakhova N., Makarov V., Buroni S. Characterization of the dispirotripiperazine derivative PDSTP as antibiotic adjuvant and antivirulence compound against Pseudomonas aeruginosa, Frontiers in Microbiology, 2024, 10.3389/fmicb.2024.1357708



18 февраля 2024 г.
(дата)